Skip to main content

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Terminated · Phase 3 · NCT05604170

Conditions: Tuberous Sclerosis Complex

At a glance

Research payments reported, 2025
$961,192
U.S. investigators named
31
Sites paid
34
Planned or actual enrollment
117

About the trial

Sponsor
Marinus Pharmaceuticals
Tested
Ganaxolone (drug)
Dates
Started 2022-05-16; completion 2025-04-02
Results posted
Yes

This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001

From ClinicalTrials.gov, last updated 2025-10-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Immedica Pharma US, Inc. reported $961,192 in research payments for this study in 2025 (207 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.